In FY2025, Journey Medical achieved $61.9 million in revenue, marking a 10.2% increase over the prior year, largely driven by the commercial launch of Emrosi. Despite this top-line improvement, the company operated at a net loss of $11.4 million, although this represented a modest improvement compared to prior years. Key drivers include proprietary drug formulations protected by Orange Book-listed patents and an effective licensing-based commercial strategy leveraging an established sales team. Challenges remain in securing payer coverage amid competitive dermatology markets and sustaining positive cash flows. Going forward, monitoring uptake of recently launched products and managing regulatory compliance are essential milestones.